Cytogen Stock Total Asset
| 217330 Stock | KRW 9,220 230.00 2.43% |
Cytogen fundamentals help investors to digest information that contributes to Cytogen's financial success or failures. It also enables traders to predict the movement of Cytogen Stock. The fundamental analysis module provides a way to measure Cytogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytogen stock.
Cytogen |
Cytogen Company Total Asset Analysis
Cytogen's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Cytogen Total Asset | 55.53 B |
Most of Cytogen's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytogen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Cytogen has a Total Asset of 55.53 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology & Medical Research industry. The total asset for all Republic of Korea stocks is 88.45% lower than that of the firm.
Cytogen Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytogen's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytogen could also be used in its relative valuation, which is a method of valuing Cytogen by comparing valuation metrics of similar companies.Cytogen is currently under evaluation in total asset category among its peers.
Cytogen Fundamentals
| Return On Equity | -96.72 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (9.92) % | |||
| Current Valuation | 324.23 B | |||
| Shares Outstanding | 5.63 M | |||
| Shares Owned By Insiders | 39.37 % | |||
| Shares Owned By Institutions | 0.05 % | |||
| Price To Sales | 487.61 X | |||
| Revenue | 347.85 M | |||
| Gross Profit | (129.63 M) | |||
| EBITDA | (5.87 B) | |||
| Net Income | (10.87 B) | |||
| Cash And Equivalents | 30.29 B | |||
| Total Debt | 20.9 B | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 16.09 X | |||
| Cash Flow From Operations | (5.23 B) | |||
| Beta | 1.16 | |||
| Market Capitalization | 95.89 B | |||
| Total Asset | 55.53 B | |||
| Z Score | 2.4 | |||
| Net Asset | 55.53 B |
About Cytogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytogen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytogen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Cytogen Stock
Cytogen financial ratios help investors to determine whether Cytogen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cytogen with respect to the benefits of owning Cytogen security.